OUR “3-C” THERAPEUTICS MODEL
At Jabez, we identify and advance cancer therapeutics that are easy to take, easy to make, and ready to combine, not recreate.
“3-C” Cancer Therapeutics are:
Convenient
Designed for ease of use; oral administration, well-tolerated profiles, and outpatient compatibility when possible.
Cost-Effective
Synthesized with scalable, tractable chemistry. Built for real-world manufacturing, storage, and distribution.
Cooperative (Synergistic)
Mechanistically synergistic with existing standards of care. We prioritize biological rationale, not empirical stacking.
We’re not redefining biology – we’re leveraging it better.
OUR APPROACH
A Biology-First Approach
We do not rely on trial-and-error combinations. We apply rigorous mechanistic reasoning to identify rationale, biological synergy up front.
Step #1
Identification & Licensing
We identify and license promising molecules with well-characterized mechanisms that align with our 3-C model and strategic synergy criteria.
Step #2
Validation & Planning
We design targeted development plans choosing the precise combinations, and patient populations to maximize impact.
Step #3
Clinical Deployment
We execute focused, efficient trials, bringing the right therapy to the right patients with precision, speed, and intent.
JBZ-001:
Our Lead Compound
JBZ-001 is an oral DHODH inhibitor currently in a Phase 1 clinical trial for advanced solid tumors and non-Hodgkin lymphoma.
It brilliantly exemplifies our 3-C model:
- Convenient: Well-tolerated, oral small molecule
- Cost-Effective: Leverages Nobel Prize-winning, scalable chemistry
- Cooperative: Displays potent synergy with well-established treatment regimens.
JBZ-001: Small Molecule DHODH Inhibitor
DHODH, JBZ-001 & Cancer
To understand how JBZ-001 fights cancer, it is important to first understand the role of DHODH. Put simply, DHODH is an enzyme that is crucial for the production of pyrimidine nucleotides – essential factors in the creation of new DNA and RNA, and vital for cell division.
Cancer cells have a very high dependence on DHODH for their survival and growth – much higher than healthy cells – and therefore are very sensitive to the loss of DHODH function. So, by binding to and inhibiting DHODH, JBZ-001 selectively targets and kills cancer cells.
OUR SYNERGISTIC THERAPEUTIC APPROACH
JBZ-001's Synergistic Potential
While JBZ-001 shows strong single-agent activity, preclinical studies have revealed two remarkable mechanisms of synergy with standard treatments in two key cancer types.
Acute Myeloid Leukemia (AML)
Enhancing AML Treatment
JBZ-001 promotes myeloid cell differentiation and has demonstrated a potent ability to enhance the activity of several AML-specific therapeutics across AML subtypes.
CD38 Antibodies (mAbs)
Increase Activity of CD38 mAbs
In both AML and multiple myeloma models, JBZ-001 increases surface expression of CD38 on tumor cells – dramatically enhancing anti-cancer activity of CD38-targeting antibodies.
Jabez Biosciences is developing a smarter model for cancer therapy.
Social Media
Jabez Biosciences. 2025. All Rights Reserved. Website made by Flyte Bio.
